Recall Notification

PharmPix Clinical Department

PharmPix is committed to the health and wellness of our members. The clinical team wants to communicate the latest up-to-date drug recall.

Recall of Three Lots of Cyclophosphamide for Injection

U.S. Food & Drug Administration Publication Date:

07/24/2026

National Drug Code:

81298-8112-1, 81298-8112-1, 81298-8114-1

Product Description:

Cyclophosphamide for Injection, USP is indicated for the treatment of various cancers, and for biopsy-confirmed minimal change nephrotic syndrome.

Batch (Lot) Number:

C23019V1, C24015V1, V24010V1

Expiration Date:

Oct-2026, Apr-2027, Mar-2027

Company:

Sunny Pharmtech, Inc.

Questions:

Call Sunny Pharmtech, Inc. at 886-3-4809168, Ext. 7205 or ra@sunnypharmtech.com, Monday through Friday from 9AM to 5PM GMT+8.

It is for this reason that we are notifying you that on July 24, 2026, the U.S. Food and Drug Administration (FDA) published a drug recall for the following product(s): Cyclophosphamide for Injection.

Reason for Recall

Sunny Pharmtech, Inc. is voluntarily recalling three lots of Cyclophosphamide for Injection, USP (1 g/vial and 2 g/vial) at the user level due to the detection of steel particulate matter in the product. To date, the company has not received any reports of adverse events or injuries related to this issue. Sunny PharmTech has notified the FDA and Cardinal Health of the recall and is working with Long Grove Pharmaceuticals and Cardinal Health to notify customers and manage the return and destruction of the affected lots.

Administration of an injectable product containing particulate matter may result in serious adverse health consequences, including the potential for death. Patients with cancer are considered particularly vulnerable, as they often have multiple underlying medical conditions, may be immunocompromised from current or previous treatments, and can have nutritional deficiencies associated with their disease. Potential complications include phlebitis, granuloma formation, vascular occlusion, and severe thromboembolic events that may be life-threatening.

Pharmacy Required Action

Identify if the product is in inventory and immediately stop using and dispensing it. The product should be returned to the place of purchase or as directed in the recall notification.

Advise patients that they should not discontinue using the medication without contacting their healthcare provider. Patients experiencing any problem while taking or using this product must contact their physician.

Description of product(s) recalled:

Product Name / Strength	Dosage Form / Package	NDC	Lot Number	Expiration Date
Cyclophosphamide for Injection, USP	1 g/vial, 50mL vial	81298-8112-1	C23019V1	Oct-2026
Cyclophosphamide for Injection, USP	1 g/vial, 50mL vial	81298-8112-1	C24015V1	Apr-2027
Cyclophosphamide for Injection, USP	2 g/vial, 100 mL vial	81298-8114-1	V24010V1	Mar-2027

Remember you can report adverse events related to this or any other drug product at MedWatch: The FDA Safety Information and Adverse Event Reporting Program by any of the following ways:

Complete and submit the MedWatch Online Voluntary Reporting Form online.

Download FDA Form 3500 or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form or submit by fax to 1-800-FDA-0178.

Additional information can be found at: MedWatch: The FDA Safety Information and Adverse Event Reporting Program.

If you have any questions or wish to have more information regarding this document, you can call us at 787-522-5252-ext.219. Our pharmacists will help you.

In addition, know that you can access our recent communications at our providers' portal: https://www.pharmpix.com/providers/.

REFERENCES:

1. U.S. Food and Drug Administration. *Sunny Pharmtech, Inc. Issues Voluntary Nationwide Recall of Cyclophosphamide for Injection, USP to the User Level Due to the Presence of Particulate Matter.* FDA, 24 July 2026. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sunny-pharmtech-inc-issues-voluntary-nationwide-recall-cyclophosphamide-injection-usp-user-level-due